GlobeNewsWire
30 Jun 2026, 16:51 UTC · 11w ago
Verdict
Headline takes no side. We score UNCY −1.00 across three claims — strongly bearish.
−1.00strongly bearish
More negative than 96% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
The FDA issued a second Complete Response Letter (CRL) regarding Unicycive Therapeutics' resubmitted OLC NDA.
So whatA second CRL indicates a failure to gain regulatory approval for a key product, significantly delaying potential revenue and impacting company valuation.
More negative than 99% of claims this week
The FDA's rejection was based on recurring third-party manufacturing deficiencies and a lack of a completed vendor inspection.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More negative than 92% of claims this week
Law firm Johnson Fistel is investigating Unicycive Therapeutics for potential securities law violations following investor losses.
More negative than 81% of claims this week
Which stocks this story touches
More negative than 96% of ticker scores this week
The company received a second FDA Complete Response Letter due to manufacturing deficiencies, leading to a stock price decline and a legal investigation.
More negative than 87% of ticker scores this week
The company is the subject of an investigation by Johnson Fistel on behalf of investors who suffered losses.
More negative than 87% of ticker scores this week
The company is the subject of an investigation by Johnson Fistel on behalf of investors who suffered losses.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
1d ago
−37.7%
Price agrees with the score
$4.80 vs $7.70 close before publication (Jun 29) · not market-adjusted
UNCY chart →
